Medicare Enrolled

Dr. Qaiser Rehman, MD

Rheumatology · Houston, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
11307 FM 1960 RD W, Houston, TX 77065
8322378585
In practice since 2006 (19 years)
NPI: 1538252374 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Rehman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rehman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Rehman

Dr. Qaiser Rehman is a rheumatology specialist in Houston, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Rehman performed 12,684 Medicare services across 1,363 unique beneficiaries.

Between the years covered by Open Payments, Dr. Rehman received a total of $2,259 from 17 pharmaceutical and/or device companies across 121 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Rehman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 37% volume in TX $2,259 industry payments

Medicare Practice Summary

Medicare Utilization ↗
12,684
Medicare services
Top 37% in TX for rheumatology
1,363
Unique beneficiaries
$28
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~668 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 5,580 $18 $58
Infliximab infusion (Remicade) 4,050 $26 $178
Office visit, established patient (20-29 min) 824 $65 $150
Steroid injection (triamcinolone) 664 $1 $5
Office visit, established patient (30-39 min) 493 $93 $175
Drug injection, under skin or into muscle 226 $11 $35
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle 145 $59 $100
Administration of chemotherapy into vein, 1 hour or less 142 $104 $350
Infusion, normal saline solution, 250 cc 127 $1 $20
Administration of chemotherapy into vein, each additional hour 123 $23 $150
Joint injection, major joint 122 $49 $150
New patient office visit, complex (60-74 min) 98 $151 $400
Aspiration and/or injection of fluid from medium joint 59 $41 $148
Injection into tendon or ligament 19 $43 $90
Aspiration and/or injection of fluid from small joint 12 $43 $125
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
32.9% high complexity
55.9% medium
11.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$2,259
Total received (2018-2024)
Avg $323/year across 7 years
Bottom 39% in TX for rheumatology
17
Companies
121
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,259 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$382
2023
$390
2022
$594
2021
$125
2020
$299
2019
$147
2018
$322

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$907
PFIZER INC.
$399
ABBVIE INC.
$253
GlaxoSmithKline, LLC.
$227
UCB, Inc.
$96
Biosense Webster, Inc.
$68
E.R. Squibb & Sons, L.L.C.
$45
Janssen Biotech, Inc.
$39
AstraZeneca Pharmaceuticals LP
$37
Mylan Institutional Inc.
$36
Novartis Pharmaceuticals Corporation
$24
Horizon Pharma plc
$24
Kyowa Kirin, Inc.
$22
AbbVie, Inc.
$21
TerSera Therapeutics LLC
$20
Aurinia Pharma U.S., Inc.
$20
Radius Health, Inc.
$19
Top 3 companies account for 69.0% of total payments
Associated products mentioned in payments ›
BENLYSTA · CARTO 3 · COSENTYX · Cimzia · Crysvita · EVENITY · Enbrel · Hulio · Humira · LUPKYNIS · LYRICA · ORENCIA · Quzyttir · RAYOS · RINVOQ · SAPHNELO · SKYRIZI · STELARA · TAVNEOS · TREMFYA · Tavneos · Tymlos · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $18 per 100 Medicare services performed
Looking for a rheumatology specialist in Houston?
Compare rheumatologists in the Houston area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
85
Per 100K population
1.8
County median income
$73,104
Nearest hospital
HOUSTON METHODIST WILLOWBROOK HOSPITAL
4.1 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Rehman is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Rehman experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Rehman performed 5,580 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rehman receive payments from pharmaceutical companies?
Yes. Dr. Rehman received a total of $2,259 from 17 companies across 121 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rehman's costs compare to other rheumatologists in Houston?
Dr. Rehman's average Medicare payment per service is $28. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rehman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →